Goldman Sachs’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-4,110
| Closed | -$32K | – | 5412 |
|
|
2022
Q3 | $32K | Sell |
4,110
-15
| -0.4% | -$117 | ﹤0.01% | 5086 |
|
|
2022
Q2 | $87K | Buy |
4,125
+15
| +0.4% | +$316 | ﹤0.01% | 5161 |
|
|
2022
Q1 | $155K | Sell |
4,110
-10
| -0.2% | -$377 | ﹤0.01% | 5177 |
|
|
2021
Q4 | $232K | Sell |
4,120
-1,120
| -21% | -$63.1K | ﹤0.01% | 4915 |
|
|
2021
Q3 | $378K | Sell |
5,240
-244
| -4% | -$17.6K | ﹤0.01% | 4531 |
|
|
2021
Q2 | $525K | Buy |
5,484
+272
| +5% | +$26K | ﹤0.01% | 4396 |
|
|
2021
Q1 | $770K | Buy |
5,212
+743
| +17% | +$110K | ﹤0.01% | 4089 |
|
|
2020
Q4 | $625K | Buy |
4,469
+133
| +3% | +$18.6K | ﹤0.01% | 3708 |
|
|
2020
Q3 | $658K | Buy |
4,336
+3,641
| +524% | +$553K | ﹤0.01% | 3529 |
|
|
2020
Q2 | $122K | Buy |
+695
| New | +$122K | ﹤0.01% | 4127 |
|
|
2017
Q3 | – | Sell |
-152
| Closed | -$39K | – | 4447 |
|
|
2017
Q2 | $39K | Buy |
+152
| New | +$39K | ﹤0.01% | 4276 |
|
|
2015
Q4 | – | Sell |
-96
| Closed | -$105K | – | 4638 |
|
|
2015
Q3 | $105K | Sell |
96
-49
| -34% | -$53.6K | ﹤0.01% | 4147 |
|
|
2015
Q2 | $146K | Buy |
+145
| New | +$146K | ﹤0.01% | 4166 |
|
|
2015
Q1 | – | Sell |
-233
| Closed | -$779K | – | 4656 |
|
|
2014
Q4 | $779K | Sell |
233
-126
| -35% | -$421K | ﹤0.01% | 3098 |
|
|
2014
Q3 | $1.04M | Sell |
359
-178
| -33% | -$517K | ﹤0.01% | 2883 |
|
|
2014
Q2 | $2.04M | Buy |
537
+198
| +58% | +$753K | ﹤0.01% | 2541 |
|
|
2014
Q1 | $1.85M | Sell |
339
-2
| -0.6% | -$10.9K | ﹤0.01% | 2602 |
|
|
2013
Q4 | $1.07M | Sell |
341
-31
| -8% | -$97.6K | ﹤0.01% | 3029 |
|
|
2013
Q3 | $1.21M | Buy |
+372
| New | +$1.21M | ﹤0.01% | 2829 |
|